Fiche société
Vertex Pharmaceuticals Incorporated
Traitements, essais et publications liés.
Traitements6programmes
Essais4liés
Publications0liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| PovetaciceptThe purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG). | Lupus, Myasthénie | Phase 2 | À vérifier | United States, Australia, Poland, Turkey (Türkiye), United Kingdom | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 2 | À vérifier | United States, Australia, Belgium, Canada, Germany, Netherlands, Spain, United Kingdom | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 2 | À vérifier | United States, Australia, Belgium, Canada, Germany, Netherlands, Spain, United Kingdom | À vérifier |
| PovetaciceptThe purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 2 | À vérifier | United States, Australia, Poland, Turkey (Türkiye), United Kingdom | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 1/2 | À vérifier | United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom | À vérifier |
| PovetaciceptThe purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG). | Lupus | Phase 1/2 | À vérifier | United States, Australia, Puerto Rico, South Korea | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Povetacicept | Lupus | Phase 1/2 | NCT05732402 | RUBY-3 — An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases | ACTIVE_NOT_RECRUITING |
| VX-670 | Myopathies | Phase 1/2 | NCT06185764 | Galileo — A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | ACTIVE_NOT_RECRUITING |
| Povetacicept | Myasthénie | Phase 2 | NCT07501702 | ETNA — A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| VX-670 | Myopathies | Phase 2 | NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | ENROLLING_BY_INVITATION |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||